Form 4: Castle Biosciences Executive Sells Shares
Insider Transaction (Form 4)
Derek J Maetzold, Pres. & Chief Exec. Officer and a Director of Castle Biosciences Inc, sold 14,518 shares of common stock on September 11, 2026.
Summary
- Option exercise/conversion: acquired 8,584 Common Stock at $2.39 ($20,516) on September 11, 2026; holds 30,063 after (Direct).
- Open-market sale: disposed of 8,361 Common Stock at $32.00 ($267,552) on September 11, 2026; holds 21,702 after (Direct).
- Open-market sale: disposed of 3,124 Common Stock at $32.00 ($99,968) on September 11, 2026; holds 14,517 after (Indirect).
- Open-market sale: disposed of 2,656 Common Stock at $32.00 ($84,992) on September 11, 2026; holds 12,339 after (Indirect).
- Open-market sale: disposed of 223 Common Stock at $32.78 ($7,310) on September 11, 2026; holds 21,479 after (Direct).
- Open-market sale: disposed of 83 Common Stock at $32.78 ($2,721) on September 11, 2026; holds 14,434 after (Indirect).
- Open-market sale: disposed of 71 Common Stock at $32.78 ($2,327) on September 11, 2026; holds 12,268 after (Indirect).
- Option exercise/conversion: disposed of 8,584 Stock option (right to buy) on September 11, 2026; holds 16,745 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $464,870 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Derek J Maetzold — Director, Officer (Pres. & Chief Exec. Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Option exercise/conversion | Common Stock | 8,584 | $2 | $20.5K | 30,063 |
| 2026-09-11 | Open-market sale | Common Stock | 8,361 | $32 | $267.6K | 21,702 |
| 2026-09-11 | Open-market sale | Common Stock | 3,124 | $32 | $100.0K | 14,517 |
| 2026-09-11 | Open-market sale | Common Stock | 2,656 | $32 | $85.0K | 12,339 |
| 2026-09-11 | Open-market sale | Common Stock | 223 | $33 | $7.3K | 21,479 |
| 2026-09-11 | Open-market sale | Common Stock | 83 | $33 | $2.7K | 14,434 |
| 2026-09-11 | Open-market sale | Common Stock | 71 | $33 | $2.3K | 12,268 |
| 2026-09-11 | Option exercise/conversion | Stock option (right to buy) | 8,584 | — | — | 16,745 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Option exercise/conversion (8,584 shares) |
| 2026-09-11 | Open-market sale (8,361 shares) |
| 2026-09-11 | Open-market sale (3,124 shares) |
| 2026-09-11 | Open-market sale (2,656 shares) |
| 2026-09-11 | Open-market sale (223 shares) |
| 2026-09-11 | Open-market sale (83 shares) |
| 2026-09-11 | Open-market sale (71 shares) |
| 2026-09-11 | Option exercise/conversion (8,584 shares) |
Keywords
insider transaction, Form 4, CSTL, CASTLE BIOSCIENCES INC, bearish, Derek J Maetzold
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.